High levels of SLFN11 (protein/mRNA) are the strongest predictors of SCLC sensitivity to PARP inhibitors (e.g., talazoparib, olaparib) and cisplatin, a finding that was validated in PDX models and 51 SCLC cell lines. Here, PARP1 is linked to small cell lung carcinoma.